ClinicalTrials.gg
Not yet recruitingNCT07858773PRE-WHEEUpdated Oct 5, 2026

Prevent Wheeze Trial

A Phase 4 interventional study of Dexamethasone 0.6 mg/kilogram body weight single dose and Placebo in Lower Respiratory Tract Infection (LRTI) and Recurrent Wheezing, sponsored by Norwegian University of Science and Technology. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 3 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Norwegian University of Science and Technology · Phase 4, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
3 Months to 24 Months
Sex
All
01

Study summary

This trial investigates whether a single dose of dexamethasone will prevent recurrent wheezing in children at high-risk for asthma admitted to hospital with a lower respiratory tract infection (LRTI). Eligible children will be identified and enrolled upon hospital admission or during hospitalisation and allocated to receive either dexamethasone 0.6 mg/kilogram body weight or the similar number of placebo tablets (allocation ratio 1:1). The follow-up is 12 months and comprises scheduled on-site examinations by physician and study nurse, scheduled phone contacts, and registrations of new LRTI-episodes (if any). Nasopharyngeal swabs and blood will be collected at specified visits. The children will be invited to a follow-up study at school age for lung function assessments.

02

Conditions studied

  • Lower Respiratory Tract Infection (LRTI)
  • Recurrent Wheezing

Keywords

  • recurrent wheezing
  • lower respiratory tract infection
  • LRTI
  • asthma
  • low- and middle-income country
  • LMIC
  • Nepal
  • pediatric
  • South Africa
  • dexamethasone
  • corticosteroids
03

In context

Respiratory Sounds

189 studies on the registry are indexed under Respiratory Sounds; 41 are open to participants now.

This study's planned enrollment of 486 is above the median of 120 across 98 interventional studies indexed under Respiratory Sounds.

Browse Respiratory Sounds studies →

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 3-24 months
  2. LRTI (WHO definition LRTI: Cough or difficulties breathing

    + plus either fast breathing ( 2-12 months: > 50 breaths/minute 13-24 months: >40/minute) or: lower chest wall indrawing (retractions/nasal flare/difficulties breathing/wheeze) Acute:\<7 days duration of LRTI symptoms

  3. No history of previous LRTI/wheeze
  4. + 1 or more risk factors for recurrent wheeze:

    • Clinical wheeze by presentation (indicated in TAL score>=1 for wheeze item). The scoring matrix is here and in the annex.
    • Indoor pollution exposure: Tobacco smoke exposure a) during pregnancy or b) in house where child lives (regular >= 2week) or polluting cooking facility
    • Atopic/allergic disease in child
    • Atopic/allergic/asthma in sibling, mother or father
    • PT week 34-36 or BW 2000-2500g
    • Eosinophil count >0.30

Exclusion criteria

Exclusion criteria:

  • Chronic illness other than atopy (eczema, food allergy),
  • Systemic treatment the previous 6 months
  • Inhaled corticosteroid treatment, at any time, for >2 weeks
  • Clinical suspicion of bacterial pneumonia based upon a temperature ≥39.0°C and at least one of the following: 1. Unilaterally decreased breath sounds or unilateral percussion dullness 2. Pulmonary lobar consolidation and/or radiological high suspicion of empyema on chest x-ray if this is obtained prior to inclusion in the trial. Fills other criteria for high likelihood of bacterial pneumonia (on clinicians' evaluation or CRP>40)
  • Evidence of any bacterial infection other than bacterial LRTI, including, but not exclusively: 1. Clinical septicemia 2. Urinary tract infection 3. Meningitis
  • participation in another trial
  • varicella infection or contact during the last 2-3 weeks
  • Fulfill criteria for ICS at time of inclusion, at treating physicians discretion, guided by annex on criteria for unblinding due to medical condition needing open CS treatment (criteria for unbinding Criteria for unblinding.docx)
  • Severe wheeze defined by TAL score* >=11 or need for intensive care unit treatment with invasive ventilation at screening.
  • Previous admission for a LRTI or physician verified LRTI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
486 participants (estimated)

Study arms

  • Active comparator
    Dexamethasone 0.6 mg/kilogram body weight single dose

    Dexamethasone 0.6 mg/kilogram body weight single dose

    Drug: Dexamethasone 0.6 mg/kilogram body weight single dose

  • Placebo comparator
    Placebo single dose

    Placebo single dose

    Drug: Placebo

Interventions

  • DrugDexamethasone 0.6 mg/kilogram body weight single dose

    Drug page: DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dexamethasone 0.6 mg/kilogram body weight single dose

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. New episode of wheeze within 12 months from inclusion, yes/no.

    Whether or not the child had any new wheezing episode within the first 12 months. Wheeze is confirmed by doctor/study nurse or caregiver history supported by viedo. Any episode of wheeze is verified by TAL criteria scoring of 1 or more on the wheeze item (end-expiratory by stethoscope=1, Entire expiration (+/-audible without stethoscope)=2, inspiratory and expiratory (audible without stethoscope)=3). Full TAL scoring is assessed and included in episode evaluation.

    Time frame: 12 months

Secondary outcomes

  1. Duration of symptoms for initial episode

    Time frame: 6 weeks (4 - 8 weeks)

  2. Number of episodes with breathing difficulty within 12 months

    Episodes of breathing difficulty by 12 months follow-up, including: new breathing difficulty with wheeze (y/n), LRTI without wheeze (y/n), and any hospital admission for breathing difficulties (y/n).

    Time frame: 12 months

  3. Time to any episode with breathing difficulties within 12 months after inclusion.

    Time in number of days.

    Time frame: 12 months

  4. Number of episodes with acute breathing difficulty (duration >24 hours) by 12 months.

    Time frame: 12 months

  5. Total number of days with breathing difficulty within 14 days of intervention.

    Time frame: 14 days

  6. Total number of days with breathing difficulty within 12 months

    Time frame: 12 months

  7. Lung function at 6 weeks (4 - 8 weeks) after inclusion

    Tidal breathing flow-volume loop (TBFVL) and oscillometry at scheduled visit 6 (4 - 8) weeks after inclusion.

    Time frame: 6 weeks

  8. Lung function 12 months after inclusion

    Tidal breathing flow-volume loop (TBFVL) and oscillometry at scheduled visit 12 months after inclusion.

    Time frame: 12 months

  9. Quality of Life 6 weeks (4 - 8 weeks) after inclusion.

    Quality of Life assessment in children aged 3 - 24 months in Nepal only. Nepali verison of the Pediatric Quality of Life Inventory Infant Scales (PedsQL).

    Time frame: 6 weeks

  10. Quality of Life 12 months after inclusion

    Quality of Life assessment in children aged 3 - 24 months in Nepal only. Nepali verison of the Pediatric Quality of Life Inventory Infant Scales (PedsQL).

    Time frame: 12 months

  11. Height development within 12 months of study entry

    Height is measured in centimeters (cm) to the nearest 0.1cm, using a calibrated stadiometer for children \>24 months of age. For children \<24 months of age, lenght is measured in the recumbent position using an infantometer. Height is measured at inclusion, 6 weeks and 12 months after inclusion.

    Time frame: 12 months

  12. Body weight development within 12 months of study entry

    Body weight in kilograms, 1 decimal. For children \>24 months of age, weight will be measured with light clothing using a calibrated electronic scale. For children \<24 months, weight will be measured without clothes or with a dry diaper only using a leveled pan scale. Body weight is measured at inclusion, 6 weeks and 12 months after inclusion.

    Time frame: 12 months

  13. Time to fulfill criteria for asthma, in accordance with GINA 2025 guidelines, within 12 months.

    Criteria meeting GINA 2025 definitions for asthma in children \<=5 years of age: 1) symptom pattern consistent with asthma and not controlled; \>=3 episodes/year or symptoms most days or 2) symptoms occurring more than two days per week with a history of severe wheezing episodes AND: response to trial treatment.

    Time frame: 12 months

07

Study locations

2 sites
  • Department of Pediatrics, Dhulikhel Hospital
    Dhulikhel, Bagmati 45200, Nepal
    • Srijana Dongol, MD · Contactdocsrijana@yahoo.com · +9779801315230
    • Rajeev Shrestha, PhD · Contactrajeev.shrestha@kusms.edu.np
    • Rajeev Shrestha, PhD · Principal investigator
    • Srijana Dongol, MD · Principal investigator
    • Dipesh Tamrakar, MD · Sub investigator
  • Department of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand
    Johannesburg, Gauteng 2050, South Africa
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2027; primary completion for Jan 2029, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 5, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Jan 30, 2029
CompletionEst.
Jan 30, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858773
Collaborators
Dhulikhel Hospital, University of Witwatersrand, South Africa
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Jan 30, 2029 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Kari R Risnes, PhD
Contact
kari.risnes@ntnu.no
+4795170397
Trude Elvebakk, MSc
Contact
trude.elvebakk@stolav.no
+4799778223
Kari R. Risnes, PhD
principal investigator · Norwegian University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion